+

WO2000070665A3 - Peptides antiangiogeniques durables - Google Patents

Peptides antiangiogeniques durables Download PDF

Info

Publication number
WO2000070665A3
WO2000070665A3 PCT/IB2000/000763 IB0000763W WO0070665A3 WO 2000070665 A3 WO2000070665 A3 WO 2000070665A3 IB 0000763 W IB0000763 W IB 0000763W WO 0070665 A3 WO0070665 A3 WO 0070665A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
angiogenic
modified
conjugates
long lasting
Prior art date
Application number
PCT/IB2000/000763
Other languages
English (en)
Other versions
WO2000070665A2 (fr
Inventor
Dominique P Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Original Assignee
Conjuchem Inc
Dominique P Bridon
Michele Rasamoelisolo
Karen Thibaudeau
Xicai Huang
Richard Beliveau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc, Dominique P Bridon, Michele Rasamoelisolo, Karen Thibaudeau, Xicai Huang, Richard Beliveau filed Critical Conjuchem Inc
Priority to AU47748/00A priority Critical patent/AU764103B2/en
Priority to JP2000619018A priority patent/JP4209086B2/ja
Priority to EP00929748A priority patent/EP1171582A2/fr
Priority to CA002373252A priority patent/CA2373252C/fr
Priority to TNTNSN00190A priority patent/TNSN00190A1/fr
Priority to SM200000031A priority patent/SM200000031A/it
Publication of WO2000070665A2 publication Critical patent/WO2000070665A2/fr
Publication of WO2000070665A3 publication Critical patent/WO2000070665A3/fr
Priority to US11/350,703 priority patent/US7741286B2/en
Priority to US12/759,153 priority patent/US20110071082A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

L'invention concerne des peptides antiangiogéniques modifiés. Les peptides modifiés sont capables de former un peptide antiangiogénique stabilisé par peptidase. Les peptides antiangiogéniques modifiés, notamment les peptides de la boucle 5 modifiés sont capables de former un conjugué avec une protéine du sang. Les conjugués sont préparés à partir de peptides antiangiogéniques, notamment des peptides de la boucle 5, par combinaison du peptide présentant un groupe réactif fonctionnel avec une protéine du sang. Des conjugués sont préparés à partir de peptides antiangiogéniques, notamment des peptides à boucle 5, par combinaison du peptide présentant un groupe réactif fonctionnel avec une protéine du sang. Les conjugués peuvent être formés in vivo ou ex vivo. Les conjugués sont administrés aux patients afin d'avoir un effet antiangiogénique.
PCT/IB2000/000763 1999-05-17 2000-05-17 Peptides antiangiogeniques durables WO2000070665A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU47748/00A AU764103B2 (en) 1999-05-17 2000-05-17 Long lasting anti-angiogenic peptides
JP2000619018A JP4209086B2 (ja) 1999-05-17 2000-05-17 長期持続性抗新脈管形成ペプチド
EP00929748A EP1171582A2 (fr) 1999-05-17 2000-05-17 Peptides antiangiogeniques durables
CA002373252A CA2373252C (fr) 1999-05-17 2000-05-17 Peptides antiangiogeniques durables
TNTNSN00190A TNSN00190A1 (fr) 2000-05-17 2000-09-29 Peptides anti-angiogeniques a action de longue duree
SM200000031A SM200000031A (it) 1999-05-17 2000-10-09 Peptidi antiangiogeni a effetto prolungato
US11/350,703 US7741286B2 (en) 1999-05-17 2006-02-08 Long lasting anti-angiogenic peptides
US12/759,153 US20110071082A1 (en) 1999-05-17 2010-04-13 Long lasting anti-angiogenic peptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US60/134,406 1999-05-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US62354300A A-371-Of-International 1999-05-17 2000-09-05
US11/350,703 Continuation US7741286B2 (en) 1999-05-17 2006-02-08 Long lasting anti-angiogenic peptides

Publications (2)

Publication Number Publication Date
WO2000070665A2 WO2000070665A2 (fr) 2000-11-23
WO2000070665A3 true WO2000070665A3 (fr) 2001-04-19

Family

ID=22463240

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000763 WO2000070665A2 (fr) 1999-05-17 2000-05-17 Peptides antiangiogeniques durables

Country Status (9)

Country Link
EP (1) EP1171582A2 (fr)
JP (3) JP4209086B2 (fr)
CN (2) CN101289500A (fr)
AU (1) AU764103B2 (fr)
CA (1) CA2373252C (fr)
SM (1) SM200000031A (fr)
TW (1) TWI300414B (fr)
WO (1) WO2000070665A2 (fr)
ZA (2) ZA200106676B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307148B2 (en) 2004-04-23 2007-12-11 Conjuchem Biotechnologies Inc. Method for purification of albumin conjugates

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
DE60226702D1 (de) 2001-02-16 2008-07-03 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
DE60204137T2 (de) 2001-05-31 2006-01-26 Conjuchem, Inc., Montreal Langwirkende fusionspeptid-inhibitoren für hiv-infektion
AU2003246500A1 (en) * 2002-07-31 2004-02-16 Conjuchem Biotechnologies Inc. Long lasting natriuretic peptide derivatives
NZ539539A (en) * 2002-09-24 2006-11-30 Frontier Biotechnologies Co HIV gp41 c-terminal peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties
CN103897031A (zh) * 2012-12-25 2014-07-02 深圳先进技术研究院 化学修饰的胸腺五肽及其合成方法
CN104892725A (zh) * 2015-05-19 2015-09-09 广州诺威生物技术有限公司 一种萘乙酰胺新化合物
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
CN110372781B (zh) * 2019-07-29 2021-11-16 深圳佳肽生物科技有限公司 恩夫韦肽的制备方法和应用
CN117186187B (zh) * 2023-07-12 2024-05-31 中国医学科学院病原生物学研究所 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290A1 (fr) * 1992-12-04 1994-06-22 Philippe Pouletty Médicaments cellulaires à ancres
WO1997023500A1 (fr) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
WO1997041824A2 (fr) * 1996-05-03 1997-11-13 Abbott Laboratories Nouveaux peptides anti-angiogeniques, polypeptides les codant et procedes d'inhibition de l'angiogenese
WO1999024074A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Nouveaux conjugues opioides et supports endogenes
WO1999024075A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Marqueurs d'affinite pour la serum-albumine humaine
WO1999048536A2 (fr) * 1998-03-23 1999-09-30 Conjuchem, Inc. Apport local d'agents therapeutiques a action prolongee
WO2000004052A2 (fr) * 1998-07-16 2000-01-27 Adprotech Limited Derives de polypeptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602290A1 (fr) * 1992-12-04 1994-06-22 Philippe Pouletty Médicaments cellulaires à ancres
WO1997023500A1 (fr) * 1995-12-13 1997-07-03 The Children's Medical Center Corporation Inhibiteur de la proliferation des cellules endotheliales, et procede d'utilisation de celui-ci
WO1997041824A2 (fr) * 1996-05-03 1997-11-13 Abbott Laboratories Nouveaux peptides anti-angiogeniques, polypeptides les codant et procedes d'inhibition de l'angiogenese
WO1999024074A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Nouveaux conjugues opioides et supports endogenes
WO1999024075A2 (fr) * 1997-11-07 1999-05-20 Conjuchem, Inc. Marqueurs d'affinite pour la serum-albumine humaine
WO1999048536A2 (fr) * 1998-03-23 1999-09-30 Conjuchem, Inc. Apport local d'agents therapeutiques a action prolongee
WO2000004052A2 (fr) * 1998-07-16 2000-01-27 Adprotech Limited Derives de polypeptides

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307148B2 (en) 2004-04-23 2007-12-11 Conjuchem Biotechnologies Inc. Method for purification of albumin conjugates

Also Published As

Publication number Publication date
JP4209086B2 (ja) 2009-01-14
SM200000031B (it) 2001-11-21
JP2003500341A (ja) 2003-01-07
CA2373252C (fr) 2007-08-07
WO2000070665A2 (fr) 2000-11-23
ZA200109110B (en) 2002-06-13
JP2009143941A (ja) 2009-07-02
AU764103B2 (en) 2003-08-07
ZA200106676B (en) 2002-07-19
CN101289500A (zh) 2008-10-22
EP1171582A2 (fr) 2002-01-16
TW200524957A (en) 2005-08-01
JP2008110986A (ja) 2008-05-15
SM200000031A (it) 2001-11-21
AU4774800A (en) 2000-12-05
TWI300414B (en) 2008-09-01
CN1698881A (zh) 2005-11-23
CA2373252A1 (fr) 2000-11-23

Similar Documents

Publication Publication Date Title
SI1180121T1 (en) Long lasting insulinotropic peptides
WO2005081711A3 (fr) Composes de monomethylvaline capables de conjugaison aux ligands
WO2006081249A3 (fr) Conjugues de proteine biologiquement actives possedant une demi-vie in vivo modifiee
WO2000066175A3 (fr) Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
WO2005097202A3 (fr) Nouvelle utilisation et methode
EP1623994A3 (fr) Protection de peptides thérapeutiques endogènes contre l'activité peptidase par conjugaison de composants sanguins
EP2112161A3 (fr) Peptides abaissant les taux de glucose sanguin
WO2001058472A3 (fr) Compositions pharmaceutiques a base de toxine botulique
WO1999048536A3 (fr) Apport local d'agents therapeutiques a action prolongee
EP1790728A3 (fr) Imagerie, diagnostic et traitement de maladie
WO2000070665A3 (fr) Peptides antiangiogeniques durables
NZ601592A (en) Recombinant elastase proteins and methods of manufacturing and use thereof
WO2003037272A3 (fr) Conjugues de polymeres/peptides thymosine alpha 1
WO2000058466A3 (fr) Analogues de flint resistant aux proteases
WO2001068676A3 (fr) Nouveaux antagonistes de la lhrh, sa production et son utilisation comme medicament
WO2004029075A3 (fr) Acides nucleiques de peptides a recaptage et distribution dans les tissus ameliores
WO2001038343A3 (fr) Hemoglobine modifiee de maniere covalente ayant une fonction de fixation d'oxygene tributaire de basses temperatures
WO2002012336A3 (fr) THERAPEUTIQUES DU TGF-β, COMPOSITIONS ET PROCEDES D'UTILISATION
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
BR9506507A (pt) Forma galênica de derivados de 5-nitro-imadazol composiçoes farmacêuticas microgrânulos gastro-protegidos de derivados de 5-nitro-imidazol e produto da combinaçao
WO2001042423A3 (fr) Compositions et procedes servant a detecter des proteines de stress
TNSN00190A1 (fr) Peptides anti-angiogeniques a action de longue duree
TW200602353A (en) Modified secretin and method of synthesizing thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 09623543

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2373252

Country of ref document: CA

Ref country code: CA

Ref document number: 2373252

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000929748

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 619018

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 47748/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000929748

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000929748

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 47748/00

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载